Stock Detail
BIOGEN IDEC INC
Sector: Biotechnology
Latest Quote @ Mon May 5 02:02:04 (15 min delayed)
| N/A |
N/A |
$226.85 |
-1.14 |
-0.50% |
1.24M |
Last Day's Data
| $226.85 |
$228.86 |
$0.00 |
0.00% |
0.00 |
$227.99 |
| $228.16 |
$224.60 |
1.00 |
53.85B |
1.38M |
36.01 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 231.03 |
228.94 |
226.77 |
224.68 |
222.51 |
Stock Profile
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies worldwide. It offers AVONEX, RITUXAN, TYSABRI, ZEVALIN, and AMEVIVE products. The company's AVONEX is approved for the treatment of relapsing forms of multiple sclerosis; RITUXAN is used in the treatment of certain B-cell non-Hodgkin's lymphomas (NHL) or B-cell NHLs; TYSABRI is approved to treat relapsing forms of MS to reduce the frequency of clinical relapses; ZEVALIN used in the treatment of cancer; and AMEVIVE treats adult patients with moderate-to-severe chronic plaque psoriasis. Biogen Idec has collaborations with Genentech, Inc.; Vernalis plc; Elan Corporation, plc; Fumapharm AG; ImmunoGen, Inc.; Sunesis Pharmaceuticals, Inc.; Cellectis SA; and Zenyaku Kogyo Co., Ltd. The company was founded in 1985. It was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec, Inc. in 2003. Biogen Idec is headquartered in Cambridge, Massachusetts.
